Ropinirole

Ropinirole Structural Formulae

Ropinirole is a nonergot derivative dopamine receptor agonist specifically tailored for the treatment of Parkinson disease, a neurodegenerative disorder marked by decreased dopamine levels in the brain.

Pharmacodynamics and Mechanism of Action

Ropinirole, chemically denoted as (roe pin' i role"), is a synthetic compound that exhibits selective activity predominantly for the D2 class of dopamine receptors. This specificity ensures minimal agonist activity for the D1 class. As a result, ropinirole offers a notable therapeutic advantage. It may be better tolerated compared to other agents such as bromocriptine or pergolide, which engage with both D1 and D2 dopamine receptor classes, often leading to a broader spectrum of side effects.

Ropinirole ball-and-stick model

Therapeutic Applications and FDA Approval

The FDA conferred its approval for ropinirole in 1997, primarily recognizing its efficacy in alleviating symptoms associated with Parkinson disease. The agency later extended its indications to encompass restless legs syndrome, a neurological disorder that triggers an uncontrollable urge to move the legs.

Ropinirole can be procured under the brand name 'Requip' and is presented in an array of dosages: 0.25, 0.50, 1, 2, 3, 4, and 5 mg tablets. Its administration typically commences at minimal dosages, and depending upon individual tolerance and therapeutic response, dosage adjustments are made. When addressing Parkinson disease, a usual regimen involves 3 to 6 mg daily, segregated into three doses, often coupled with levodopa/carbidopa. An inherent merit of ropinirole over its counterparts, bromocriptine and pergolide, is its quicker initiation without evoking marked hypotension and nausea—commonly linked with ergot derivatives. For individuals grappling with restless legs syndrome, the initiation dosage is usually set at 0.25 mg, consumed 1 to 3 hours pre-bedtime, with subsequent adjustments rooted in tolerance and therapeutic outcome.

Hepatic Implications

While ropinirole administration is largely deemed safe, there is a scant rate of transient serum enzyme elevations during its therapeutic course. A handful of acute liver injury instances have also been attributed to ropinirole, although such cases are notably rare.

Adverse Effects

As with most therapeutic agents, ropinirole is not devoid of side effects. Commonly reported adverse reactions encompass somnolence, fatigue, vivid dream experiences, anxiety, confusion, depression, dizziness, headache, and gastrointestinal disturbances. These manifestations are consistent with the symptoms typically associated with dopaminergic stimulation.

See Also

• Dopamine receptor agonists
• Parkinson disease
• Restless legs syndrome

References

• Dailymed label info on Ropinirole
• FDA Ropinirole